Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
S Afr Med J ; 112(4): 252-258, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35587803

ABSTRACT

Articles on teenage pregnancies have been proliferating in both the popular press and the medical media. We analysed data available in the public sector database, the District Health Information System, from 2017 to 2021. During this time, the number of births to young teenagers aged 10 - 14 years increased by 48.7% (from a baseline of 2 726, which is very high by developed-country standards) and the birth rate per 1 000 girls in this age category increased from 1.1 to 1.5. These increases occurred year on year in most provinces. In adolescent girls aged 15 - 19, the number of births increased by 17.9% (from a baseline of 114 329) and the birth rate per 1 000 girls in this age category increased from 49.6 to 55.6. These increases also occurred year on year in a continuous upward trend as well as in all provinces, but at different rates. Generally, rates were higher in the more rural provinces such as Limpopo, Mpumalanga and Eastern Cape than in more urban provinces such as Gauteng and Western Cape. The increases during the past 2 years were particularly large and may be due to disruption of health and school services with decreased access to these as a result of COVID-19. These metrics pose serious questions to society in general and especially to the health, education and social sectors, as they reflect socioeconomic circumstances (e.g. sexual and gender-based violence, economic security of families, school attendance) as well as inadequate health education, life skills and access to health services.


Subject(s)
COVID-19 , Pregnancy in Adolescence , Adolescent , Female , Humans , Pregnancy , Public Sector , Sexual Behavior , South Africa/epidemiology
2.
S Afr Med J ; 108(8): 629-631, 2018 Jul 25.
Article in English | MEDLINE | ID: mdl-30182875

ABSTRACT

The World Health Organization (WHO) published guidelines for hormonal contraceptive eligibility for women at high risk of HIV in March 2017. This guidance followed from a technical consultative meeting convened by the WHO in December 2016, where all the available evidence on hormonal contraceptives and risk of HIV acquisition was reviewed. This was an expert meeting with representation from global experts in family planning and HIV management, including clinicians, epidemiologists, researchers and civil society. The guideline development group, through a consensus, made recommendations to change the medical eligibility criteria for contraceptive use from category 1 to category 2 for progestogen-only injectable contraceptives among women at high risk of HIV. There was no change in the recommendation for all other methods of hormonal contraception. The data that informed this decision are from observational studies, which have limitations; therefore, causality or association of hormonal contraception and risk of HIV acquisition have not been proven. This guidance will have an impact on countries that have a high HIV disease burden and where progestogen-only injectable contraceptives are the highest used, as in South Africa (SA). The information has to be communicated in line with the WHO's sexual and reproductive health rights principles of ensuring that all women should receive evidence-based recommendations. This will empower them to make informed choices about their reproductive needs. This article seeks to clarify the decision-making process of the WHO and how the new recommendations were formulated. It also gives SA's response to the guidance and a perspective of what informed the National Department of Health's position, taking into account the effect this will have on SA's contraceptive guidelines.


Subject(s)
Contraceptive Agents, Female , HIV Infections , Medroxyprogesterone Acetate , Practice Guidelines as Topic , Progestins , World Health Organization , Contraceptive Agents, Female/adverse effects , Female , HIV Infections/epidemiology , HIV Infections/etiology , Humans , Injections , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/adverse effects , Patient Selection , Progestins/administration & dosage , Progestins/adverse effects , Risk Assessment , South Africa
3.
S Afr Med J ; 107(11): 933-938, 2017 Oct 01.
Article in English | MEDLINE | ID: mdl-29399422

ABSTRACT

In 2014, South Africa (SA) introduced the subdermal contraceptive implant with the aim of expanding the contraceptive method mix and availability of long-acting reversible methods in the public sector. Three years on, concerns have been raised about the decline in uptake, early implant removals and challenges in service delivery. This article explores the lessons learnt from the introduction of contraceptive technologies elsewhere and applies these to the SA context. Drawing on the World Health Organization's conceptual framework for the introduction of new contraceptive methods, and subsequent literature on the topic, lessons are classified into six cross-cutting themes. Recommendations highlight the need for SA to review and explore strategies to strengthen current implant services, including the provision of improved provider training aimed at sensitive, client-centred approaches; increased community engagement; and improved systems for programmatic monitoring and evaluation. With implementation of these recommendations, worrying trends in the provision of implants could be reversed.


Subject(s)
Contraception , Family Planning Services , Long-Acting Reversible Contraception , Contraception/instrumentation , Contraception/statistics & numerical data , Device Removal/statistics & numerical data , Family Planning Services/methods , Family Planning Services/standards , Family Planning Services/statistics & numerical data , Female , Humans , Long-Acting Reversible Contraception/methods , Long-Acting Reversible Contraception/statistics & numerical data , Needs Assessment , Public Sector , Quality Improvement , South Africa
SELECTION OF CITATIONS
SEARCH DETAIL
...